Le Lézard
Classified in: Science and technology
Subject: LAW

Cyph and Zoom Patent Cross-License


CLAYMONT, Del., June 9, 2023 /PRNewswire/ -- Cyph, a leading provider of quantum-resistant cryptography technologies built by former SpaceX engineers (https://www.cyph.com) has announced that it has reached a settlement agreement with Zoom Video Communications, Inc. to resolve their patent infringement lawsuit.

Full terms of the settlement remain confidential, and each party has agreed to cross-license certain patent assets from the other.

Media contact: [email protected]

 

SOURCE Cyph


These press releases may also interest you

1 jun 2024
Live from ASCO 2024 | Ascentage Pharma Releases Updated Data of FAK/ALK/ROS1 Inhibitor APG-2449 in Patients with NSCLC
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data of its novel drug candidate...

1 jun 2024
Innovent Presents at the 2024 ASCO Annual Meeting on Clinical Data of anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Pancreatic Cancer or Biliary Tract Cancer
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

1 jun 2024
Innovent Presents Phase 1 Clinical Data of First-in-class PD-1/IL-2? Bispecific Antibody Fusion Protein (IBI363) in Melanoma, Colorectal Cancer and other Solid Tumors at the 2024 ASCO Annual Meeting
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other major...

1 jun 2024
Innovent Announces Data from Pivotal Phase 2 TRUST-I Study of Taletrectinib?ROS1 Inhibitor) are Published in the JCO and Reported at 2024 ASCO Annual Meeting
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

1 jun 2024
GenFleet Therapeutics Announces Efficacy & Safety Result from Phase II Trial for First-line NSCLC Treatment in KROCUS Study, fulzerasib (KRAS G12C Inhibitor) in Combination with cetuximab, in a Late-breaking Abstract at the Oral Presentation of 2024 ASCO Annual Meeting
GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the phase II trial data of KROCUS Study, fulzerasib (GFH925, KRAS G12C inhibitor) in combination with...

1 jun 2024
Sapience Therapeutics Presents Positive Clinical and Biomarker Data from ST101 Phase 2 Study in GBM at ASCO 2024 in Oral Presentation
Sapience Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of peptide therapeutics to address oncogenic and immune dysregulation that drive cancer, today...

More news about Science and technology...


News published on and distributed by: